LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 162

Search options

  1. Article: Smudge cells in CD200

    Jain, Preetesh / Han, Xin / Wang, Michael / Tang, Guilin

    Blood research

    2022  Volume 57, Issue 2, Page(s) 85

    Language English
    Publishing date 2022-05-13
    Publishing country Korea (South)
    Document type Case Reports
    ZDB-ID 2711910-5
    ISSN 2288-0011 ; 2287-979X
    ISSN (online) 2288-0011
    ISSN 2287-979X
    DOI 10.5045/br.2022.2020113
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.

    Jain, Preetesh / Wang, Michael L

    American journal of hematology

    2022  Volume 97, Issue 5, Page(s) 638–656

    Abstract: The field of mantle cell lymphoma (MCL) has witnessed remarkable progress due to relentless advances in molecular pathogenesis, prognostication, and newer treatments. MCL consists of a spectrum of clinical subtypes. Rarely, atypical cyclin D1-negative ... ...

    Abstract The field of mantle cell lymphoma (MCL) has witnessed remarkable progress due to relentless advances in molecular pathogenesis, prognostication, and newer treatments. MCL consists of a spectrum of clinical subtypes. Rarely, atypical cyclin D1-negative MCL and in situ MCL neoplasia are identified. Prognostication of MCL is further refined by identifying somatic mutations (such as TP53, NSD2, KMT2D), methylation status, chromatin organization pattern, SOX-11 expression, minimal residual disease (MRD), and genomic clusters. Lymphoid tissue microenvironment studies demonstrated the role of B-cell receptor signaling, nuclear factor kappa B (NF-kB), colony-stimulating factor (CSF)-1, the CD70-SOX-11 axis. Molecular mechanism of resistance, mutation dynamics, and pathogenic pathways (B-cell receptor (BCR), oxidative phosphorylation, and MYC) were identified in mediating resistance to various treatments (bruton tyrosine kinase (BTK) inhibitors [ibrutinib, acalabrutinib]. Treatment options range from conventional chemoimmunotherapy and stem cell transplantation (SCT) to targeted therapies against BTK (covalent and noncovalent), Bcl2, ROR1, cellular therapy such as anti-CD19 chimeric antigen receptor therapy (CAR-T), and most recently bispecific antibodies against CD19 and CD20. MCL patients frequently relapse. Complex pathogenesis and the management of patients with progression after treatment with BTK/Bcl2 inhibitors and CAR-T (triple-resistant MCL) remain a challenge. Next-generation clinical trials incorporating newer agents and concurrent translational and molecular investigations are ongoing.
    MeSH term(s) Adult ; Agammaglobulinaemia Tyrosine Kinase ; Antineoplastic Agents/therapeutic use ; Humans ; Lymphoma, Mantle-Cell/drug therapy ; Lymphoma, Mantle-Cell/therapy ; Neoplasm Recurrence, Local/drug therapy ; Risk Assessment ; Tumor Microenvironment
    Chemical Substances Antineoplastic Agents ; Agammaglobulinaemia Tyrosine Kinase (EC 2.7.10.2)
    Language English
    Publishing date 2022-04-19
    Publishing country United States
    Document type Journal Article
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.26523
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1251: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma.

    Deshpande, Anagha / Wang, Yucai / Munoz, Javier / Jain, Preetesh

    Drugs of today (Barcelona, Spain : 1998)

    2022  Volume 58, Issue 6, Page(s) 283–298

    Abstract: In July 2020, the U.S. Food and Drug Administration (FDA) approved brexucabtagene autoleucel (BA), the first anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed/refractory mantle cell lymphoma (MCL). The pivotal ZUMA-2 ... ...

    Abstract In July 2020, the U.S. Food and Drug Administration (FDA) approved brexucabtagene autoleucel (BA), the first anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed/refractory mantle cell lymphoma (MCL). The pivotal ZUMA-2 trial led to the approval of BA in patients who experienced relapsed disease on prior therapies (chemotherapy and/or Bruton tyrosine kinase [BTK] inhibitors). The FDA approval of BA was based on excellent responses with this therapy in highly refractory patients with MCL, who conventionally had poor outcomes. Longer follow-up data from the ZUMA-2 study have been presented at recent international meetings. As is common with other CAR T-cell therapies in lymphomas, the main toxicities of BA therapy included cytokine release syndrome (CRS), infections, cytopenias and CAR-associated neurotoxicity. In this review, we provide a summary of the data in the development of BA and its impact on MCL patient survival and future directions.
    MeSH term(s) Adult ; Antigens, CD19 ; Humans ; Immunotherapy, Adoptive/adverse effects ; Lymphoma, Mantle-Cell/drug therapy ; Receptors, Chimeric Antigen
    Chemical Substances Antigens, CD19 ; Receptors, Chimeric Antigen ; brexucabtagene autoleucel (4MD2J2T8SJ)
    Language English
    Publishing date 2022-04-13
    Publishing country Spain
    Document type Journal Article ; Review
    ISSN 1699-3993
    ISSN 1699-3993
    DOI 10.1358/dot.2022.58.6.3378055
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article: Zanubrutinib in lymphoproliferative disorders: a comprehensive review.

    Muñoz, Javier / Wang, Yucai / Jain, Preetesh / Wang, Michael

    Therapeutic advances in hematology

    2022  Volume 13, Page(s) 20406207221093980

    Abstract: The availability of Bruton tyrosine kinase (BTK) inhibitors has brought about a paradigm shift in the treatment of patients with B-cell lymphomas and chronic lymphocytic leukemia. BTK was clinically validated as a target by the efficacy of the first-in- ... ...

    Abstract The availability of Bruton tyrosine kinase (BTK) inhibitors has brought about a paradigm shift in the treatment of patients with B-cell lymphomas and chronic lymphocytic leukemia. BTK was clinically validated as a target by the efficacy of the first-in-class inhibitor ibrutinib. The extended survival conferred by BTK inhibitors has brought long-term tolerability to the foreground. To minimize toxicities thought to be attributable to off-target kinase inhibition, a next generation of BTK inhibitors with greater selectivity was developed. In the United States, zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle cell lymphoma who have received at least one prior therapy, for adults with Waldenström macroglobulinemia, and for adults with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based therapy. Because few head-to-head comparative trials of BTK inhibitors have so far been reported, no BTK 'inhibitor of choice' can be identified. Zanubrutinib has promising efficacy in its approved indications and appears to have reduced cardiac toxicities, particularly atrial fibrillation, which may influence the choice of BTK inhibitor treatment by prescribers. Further studies are needed to inform on optimal treatment sequencing of zanubrutinib and its combination with other agents. Here, we summarize existing clinical evidence for its efficacy and safety in mantle cell lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and other B-lymphoproliferative indications.
    Plain language summary: Zanubrutinib is a drug that was shown to effectively treat cancer of B cells without causing excessive serious side effects
    Language English
    Publishing date 2022-05-27
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2585183-4
    ISSN 2040-6215 ; 2040-6207
    ISSN (online) 2040-6215
    ISSN 2040-6207
    DOI 10.1177/20406207221093980
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Carcinocythemia-Cancer cell leukemia.

    Jain, Preetesh / Wang, Xiaohong Iris

    American journal of hematology

    2020  Volume 96, Issue 3, Page(s) 397–398

    MeSH term(s) Adenocarcinoma/blood ; Adenocarcinoma/secondary ; Adenocarcinoma/therapy ; Androgen Antagonists/therapeutic use ; Antineoplastic Agents, Hormonal/therapeutic use ; Bone Marrow/pathology ; Cauda Equina Syndrome/etiology ; Cell Nucleus/ultrastructure ; Combined Modality Therapy ; Humans ; Male ; Middle Aged ; Neoplastic Cells, Circulating ; Pancytopenia/etiology ; Pleural Effusion, Malignant/etiology ; Prostatic Neoplasms/blood ; Prostatic Neoplasms/complications ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/therapy ; Spinal Neoplasms/complications ; Spinal Neoplasms/drug therapy ; Spinal Neoplasms/radiotherapy ; Spinal Neoplasms/secondary ; Spinal Stenosis/etiology ; Thrombocytopenia/blood
    Chemical Substances Androgen Antagonists ; Antineoplastic Agents, Hormonal
    Language English
    Publishing date 2020-07-14
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.25902
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1251: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Concurrent myelodysplasia and monoclonal B lymphocytosis in VEXAS syndrome.

    Wilson, Nathaniel R / Jain, Preetesh / Gomez, Jesus A / Lu, Huifang / Pemmaraju, Naveen

    Leukemia research

    2022  Volume 120, Page(s) 106909

    MeSH term(s) Humans ; Lymphocytosis/diagnosis ; Myelodysplastic Syndromes/complications ; Myelodysplastic Syndromes/diagnosis
    Language English
    Publishing date 2022-06-30
    Publishing country England
    Document type Letter ; Research Support, N.I.H., Extramural
    ZDB-ID 752396-8
    ISSN 1873-5835 ; 0145-2126
    ISSN (online) 1873-5835
    ISSN 0145-2126
    DOI 10.1016/j.leukres.2022.106909
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1321: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Blastoid Mantle Cell Lymphoma.

    Jain, Preetesh / Wang, Michael

    Hematology/oncology clinics of North America

    2020  Volume 34, Issue 5, Page(s) 941–956

    Abstract: Blastoid and pleomorphic mantle cell lymphoma (MCL) are among the worst prognostic, aggressive histology, high-risk variants of MCL, and, in this article, they are presented as blastoid MCL. Blastoid MCL have not been systematically studied, probably due ...

    Abstract Blastoid and pleomorphic mantle cell lymphoma (MCL) are among the worst prognostic, aggressive histology, high-risk variants of MCL, and, in this article, they are presented as blastoid MCL. Blastoid MCL have not been systematically studied, probably due to their rarity. De novo blastoid MCLs have superior outcomes compared with transformed MCL. Compared with classic MCL, extranodal involvement (mainly skin, central nervous system), frequent relapses, and inferior responses to conventional chemoimmunotherapy, BTK inhibitors and venetoclax are frequent in blastoid MCL. KTE-X19 induces excellent response in blastoid MCL. Combinations with novel agents are actively investigated. This article presents a comprehensive review on blastoid MCL in 2020.
    MeSH term(s) Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Humans ; Immunotherapy, Adoptive ; Lymphoma, Mantle-Cell/classification ; Lymphoma, Mantle-Cell/diagnosis ; Lymphoma, Mantle-Cell/therapy ; Neoplasm Recurrence, Local ; Receptors, Chimeric Antigen ; Sulfonamides/therapeutic use
    Chemical Substances Bridged Bicyclo Compounds, Heterocyclic ; Receptors, Chimeric Antigen ; Sulfonamides ; brexucabtagene autoleucel (4MD2J2T8SJ) ; venetoclax (N54AIC43PW)
    Language English
    Publishing date 2020-08-05
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 93115-9
    ISSN 1558-1977 ; 0889-8588
    ISSN (online) 1558-1977
    ISSN 0889-8588
    DOI 10.1016/j.hoc.2020.06.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Se 1077: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner.

    Munoz, Javier L / Wang, Yucai / Jain, Preetesh / Wang, Michael

    Current oncology reports

    2022  Volume 24, Issue 10, Page(s) 1299–1311

    Abstract: Purpose of review: This review focuses on the feasibility of combining Bruton's tyrosine kinase (BTK) inhibitors (BTKis) with chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). ... ...

    Abstract Purpose of review: This review focuses on the feasibility of combining Bruton's tyrosine kinase (BTK) inhibitors (BTKis) with chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). Potential scenarios for combination treatment with these agents are presented.
    Recent findings: BTKis and CAR T-cell therapy have revolutionized the treatment paradigm for R/R MCL. Ibrutinib, acalabrutinib, and zanubrutinib are covalent irreversible BTKis approved for R/R MCL. Brexucabtagene autoleucel was the first CAR T-cell therapy approved for R/R MCL based on findings from the ZUMA-2 trial. There is evidence to suggest that combination treatment with BTKis and CAR T-cell therapy may improve CAR T-cell efficacy. As BTKis and CAR T-cell therapy become mainstays in R/R MCL therapy, combination treatment strategies should be evaluated for their potential benefit in R/R MCL.
    MeSH term(s) Adult ; Agammaglobulinaemia Tyrosine Kinase ; Antineoplastic Agents/therapeutic use ; Humans ; Immunotherapy, Adoptive ; Lymphoma, Mantle-Cell/therapy ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use
    Chemical Substances Antineoplastic Agents ; Protein Kinase Inhibitors ; Agammaglobulinaemia Tyrosine Kinase (EC 2.7.10.2)
    Language English
    Publishing date 2022-05-21
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2057359-5
    ISSN 1534-6269 ; 1523-3790
    ISSN (online) 1534-6269
    ISSN 1523-3790
    DOI 10.1007/s11912-022-01286-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5521: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: "Triple hit" SOX11

    Jain, Preetesh / Tang, Guilin / Li, Shaoying / Wang, Michael

    American journal of hematology

    2020  Volume 96, Issue 1, Page(s) 165–166

    MeSH term(s) Female ; Humans ; Lymphoma, Mantle-Cell/diagnostic imaging ; Lymphoma, Mantle-Cell/genetics ; Lymphoma, Mantle-Cell/pathology ; Middle Aged ; Mutation ; Positron Emission Tomography Computed Tomography ; SOXC Transcription Factors/deficiency ; Tumor Suppressor Protein p53/genetics
    Chemical Substances SOX11 protein, human ; SOXC Transcription Factors ; TP53 protein, human ; Tumor Suppressor Protein p53
    Language English
    Publishing date 2020-05-15
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.25848
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1251: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management.

    Jain, Preetesh / Dreyling, Martin / Seymour, John F / Wang, Michael

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2020  Volume 38, Issue 36, Page(s) 4302–4316

    MeSH term(s) Aged ; Humans ; Lymphoma, Mantle-Cell/drug therapy ; Risk Factors
    Language English
    Publishing date 2020-10-19
    Publishing country United States
    Document type Journal Article
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.20.02287
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1847: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 650: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top